Theranos Lessons: Spotting Health Tech Red Flags

Learnings from Theranos

The Theranos scandal serves as a critical reminder of the importance of transparency and credibility in health tech. With the recent documentary, many are left questioning whether new ventures are genuine innovations or just elaborate facades.

New Ventures and Familiar Patterns

Former Theranos CEO Elizabeth Holmes and partner Billy Evans have recently initiated a new project named Haemanthus. This endeavor aims to develop a diagnostic device relying on laser technology. Although marketed as innovative, this approach raises questions, considering Holmes’ history with misleading claims.

Understanding Laser Technology

Haemanthus employs Raman spectroscopy—a technique that uses lasers to analyze chemical structures. This technology isn’t revolutionary; it has been around since 1928 and is already utilized in various medical applications. The challenge lies not in the use of lasers themselves but in the claims that they can fundamentally change diagnostic practices.

Recognizing Health Tech Hype

When evaluating health tech startups, there are several key indicators to look for to avoid falling victim to misleading claims:

• Magic vs. Reality: Technology is not magic; it is a tool. Be wary of companies that present their innovations as miraculous solutions. Genuine advancements come with clear explanations of their limitations and capabilities.
• Regulatory Timelines: The rapid development of health tech is often improbable. Medical devices typically undergo rigorous testing, which can take years. If a startup claims to deliver results at breakneck speed, proceed with caution.
• Lack of Transparency: Companies should be open about their research. The best health tech firms publish their findings in reputable journals. If a startup operates in secrecy without peer-reviewed studies, it might be wise to question its credibility.

Proximity to Proven Techniques

The tools that Haemanthus aim to utilize, while promising, are not new. Existing technologies take time to develop and validate. For instance, continuous glucose monitors required decades of advancements to achieve reliability. Expecting a brand-new invention to overcome established methods effortlessly is both unrealistic and potentially deceptive.

Editor’s Note: The Continuing Relevance of Theranos

The cautionary tale of Theranos is far from finished. As Holmes and Evans embark on their latest venture, it highlights the necessity for vigilance within the health tech industry. The allure of breakthrough technology can cloud judgment, making it essential to critically assess the authenticity of any new health-related service or product.

In a world eager for quick fixes, the enduring effects of the Theranos saga remind us to verify rather than blindly trust.